newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

- IPO raised an aggregate of approximately $149.1 million in gross proceeds - Strong cash position of $198.6 million to be used to deliver expected key value-creating milestones and fund operations through 2023 - Lead program, CYT-0851, advancing